227. Osler disease
49 clinical trials,   69 drugs   (DrugBank: 21 drugs),   23 drug target genes,   132 drug target pathways

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03910244
(ClinicalTrials.gov)
October 17, 20198/4/2019Pomalidomide for the Treatment of Bleeding in HHTPomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic TelangiectasiaTelangiectasia, Hereditary HemorrhagicDrug: Pomalidomide Oral Product;Drug: Placebo oral capsuleThe Cleveland ClinicRTI InternationalActive, not recruiting18 Years99 YearsAll2Phase 2United States
2NCT02287558
(ClinicalTrials.gov)
January 27, 20156/11/2014Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I StudyA Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory AngiodysplasiaHereditary Hemorrhagic Telangiectasia;Idiopathic Vascular EctasiaDrug: PomalidomideThe Cleveland ClinicNULLCompleted18 YearsN/AAll9Phase 1United States